EP0715619A4 - Inhibiteurs de la secretion de facteur alpha de necrose tumorale - Google Patents

Inhibiteurs de la secretion de facteur alpha de necrose tumorale

Info

Publication number
EP0715619A4
EP0715619A4 EP94925940A EP94925940A EP0715619A4 EP 0715619 A4 EP0715619 A4 EP 0715619A4 EP 94925940 A EP94925940 A EP 94925940A EP 94925940 A EP94925940 A EP 94925940A EP 0715619 A4 EP0715619 A4 EP 0715619A4
Authority
EP
European Patent Office
Prior art keywords
tumor necrosis
alpha factor
factor secretion
secretion inhibitors
necrosis alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP94925940A
Other languages
German (de)
English (en)
Other versions
EP0715619A1 (fr
Inventor
Roy A Black
Jeffrey N Fitzner
Paul R Sleath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of EP0715619A1 publication Critical patent/EP0715619A1/fr
Publication of EP0715619A4 publication Critical patent/EP0715619A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Extrusion Moulding Of Plastics Or The Like (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EP94925940A 1993-08-23 1994-08-19 Inhibiteurs de la secretion de facteur alpha de necrose tumorale Ceased EP0715619A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11060193A 1993-08-23 1993-08-23
US110601 1993-08-23
US18301994A 1994-01-18 1994-01-18
US183019 1994-01-18
PCT/US1994/009343 WO1995006031A1 (fr) 1993-08-23 1994-08-19 Inhibiteurs de la secretion de facteur alpha de necrose tumorale

Publications (2)

Publication Number Publication Date
EP0715619A1 EP0715619A1 (fr) 1996-06-12
EP0715619A4 true EP0715619A4 (fr) 1997-03-19

Family

ID=26808203

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94925940A Ceased EP0715619A4 (fr) 1993-08-23 1994-08-19 Inhibiteurs de la secretion de facteur alpha de necrose tumorale

Country Status (8)

Country Link
EP (1) EP0715619A4 (fr)
JP (1) JPH09503201A (fr)
AU (2) AU687436B2 (fr)
CA (1) CA2170158A1 (fr)
FI (1) FI960803A7 (fr)
NO (1) NO960723D0 (fr)
NZ (1) NZ271893A (fr)
WO (1) WO1995006031A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9509237A (pt) * 1994-10-05 1997-10-21 Chiroscience Ltd Compostos peptidila e seu uso terapêutico como inibidores de metaloproteases
CA2217857A1 (fr) * 1995-05-10 1996-11-14 Darwin Discovery Limited Composes peptidiques inhibant la liberation de la metalloproteinase et du tnf et leur utilisation therapeutique
US5994293A (en) * 1995-05-10 1999-11-30 Darwin Discovery Ltd. Peptidyl compounds and their therapeutic use
JPH11505532A (ja) * 1995-05-10 1999-05-21 カイロサイエンス・リミテッド 金属プロテアーゼとｔｎｆの放出を抑制するペプチド化合物およびその治療的使用
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
EP0789758A2 (fr) * 1995-09-05 1997-08-20 Celltech Therapeutics Limited Codage de sequences d'adn destine a une metalloproteinase humaine et ses variants
HUP0003760A3 (en) * 1995-10-05 2001-05-28 Darwin Discovery Ltd Cambridge Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation, process for production thereof and their use
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
ES2164264T3 (es) 1995-11-23 2002-02-16 British Biotech Pharm Inhibidores de metaloproteinasas.
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US5990293A (en) * 1996-09-05 1999-11-23 Celltech Therapeutics Limited Human metalloproteinase, variants thereof and DNA sequence coding therefor
BR9712019A (pt) 1996-09-10 1999-08-24 British Biotech Pharm Derivados de cidos hirox-mico citoest ticos
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
ZA9818B (en) * 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
AU730308B2 (en) * 1997-06-18 2001-03-01 Rockefeller University, The Methods for identifying antibodies and peptides useful in the treatment of septic shock and experimental arthritis and uses thereof
EP1021173A1 (fr) * 1997-10-10 2000-07-26 Imperial College Innovations Limited Emploi de composes de csaid?tm pour le traitement des contractions uterines
GB9810464D0 (en) 1998-05-16 1998-07-15 British Biotech Pharm Hydroxamic acid derivatives
US6172064B1 (en) 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
GB9818605D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therepeutic agents
US6329400B1 (en) 1998-08-26 2001-12-11 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
EP1117372A2 (fr) * 1998-09-30 2001-07-25 The Procter & Gamble Company Procede de traitement de la chute de cheveux par administration de sulfonamides
CN1367678A (zh) * 1998-09-30 2002-09-04 宝洁公司 使用酮酰胺治疗脱发的方法
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
EP1143941A3 (fr) * 1999-01-13 2002-02-06 Jomaa Pharmaka GmbH Utilisation de 3-isoxazolidinones et d'hydroxylaminoacides pour le traitement d'infections
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
AU2001271068A1 (en) * 2000-07-18 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
AU2002230385A1 (en) * 2000-09-25 2002-04-15 Questcor Pharmaceuticals, Inc. Peptide deformylase inhibitors
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
EP3860608A1 (fr) 2018-10-04 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiteurs de l'egfr pour traiter les kératodermies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2268933A (en) * 1992-07-23 1994-01-26 British Bio Technology Hydroxysuccinyl hydroxyamines
WO1995013289A1 (fr) * 1993-11-10 1995-05-18 Chiroscience Limited Composes peptidyles et leur utilisation therapeutique en tant qu'inhibiteurs des metalloproteases
WO1995033709A1 (fr) * 1994-06-03 1995-12-14 F. Hoffmann-La Roche Ag Derives hydroxylamine et leur utilisation en tant qu'agents d'inhibition des metalloproteinases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0207097B1 (fr) * 1984-12-19 1990-08-08 Ciba-Geigy Ag Nouveaux esters d'acide carbonique
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
WO1992022523A2 (fr) * 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Derives peptidiques utilises comme inhibiteurs de collagenase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2268933A (en) * 1992-07-23 1994-01-26 British Bio Technology Hydroxysuccinyl hydroxyamines
WO1995013289A1 (fr) * 1993-11-10 1995-05-18 Chiroscience Limited Composes peptidyles et leur utilisation therapeutique en tant qu'inhibiteurs des metalloproteases
WO1995033709A1 (fr) * 1994-06-03 1995-12-14 F. Hoffmann-La Roche Ag Derives hydroxylamine et leur utilisation en tant qu'agents d'inhibition des metalloproteinases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9506031A1 *

Also Published As

Publication number Publication date
FI960803L (fi) 1996-04-22
JPH09503201A (ja) 1997-03-31
AU5030298A (en) 1998-03-05
FI960803A7 (fi) 1996-04-22
NZ271893A (en) 1997-11-24
AU7569494A (en) 1995-03-21
FI960803A0 (fi) 1996-02-22
NO960723L (no) 1996-02-23
AU687436B2 (en) 1998-02-26
CA2170158A1 (fr) 1995-03-02
NO960723D0 (no) 1996-02-23
EP0715619A1 (fr) 1996-06-12
WO1995006031A1 (fr) 1995-03-02

Similar Documents

Publication Publication Date Title
EP0715619A4 (fr) Inhibiteurs de la secretion de facteur alpha de necrose tumorale
FI980038L (fi) Tuumorinekroositekijän alfa inhibiittoreita
FI941459A0 (fi) Tuumorinekroositekijän muteiineja
EP1100886A4 (fr) Facteur de necrose tumorale gamma
FI945706A7 (fi) Proteiinikinaasi C-inhibiittoreita
EP0619982A3 (fr) Ancre chirurgicale.
DE59200089D1 (de) Hochdruckentladungslampe kleiner Leistung.
BR9710453A (pt) Inhibidor de produ-Æo de citocina composto de triazepina e intermedi rio para o mesmo
DE69208107D1 (de) Kältemittel
DE69435267D1 (de) Proteinkinase C Inhibitoren
ATE172199T1 (de) Proteinkinase-c-inhibitor
FI922434L (fi) Produktion av rekombinant human interleukin-1-inhibitor.
DE69323185D1 (de) Proteinkinase c-inhibitor
FR2701264B1 (fr) Muteines de facteur de necrose tumorale.
IL114418A0 (en) Tumor necrosis factor receptor-II associated protein kinase and methods for its use
DE69214408D1 (de) Strahlende Hochfrequenzleitung
DE69605683D1 (de) Lebensmitteldressing
KR930702896A (ko) 종양괴사인자 억제제
DE69012260D1 (de) Bioaktiver Zement.
IL126873A0 (en) Alkyloxyamino substituted fluorenones and their use as protein kinase c inhibitors
FI101796B1 (fi) Uusia -glukosidaasi-inhibiittoreita
EP1159286A4 (fr) Recepteurs du facteur de necrose tumorale 6 alpha et 6 beta
EP0663210A3 (fr) Inhibiteurs de la production du facteur nécrosant des tumeurs.
ITMI921618A1 (it) Bersaglio apparente multispettrale
EP0797592A4 (fr) Stanniocalcine-alpha humaine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19980515

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19990823